Back to search

Ireland· IE-PA-EU/1/00/142/14-16

NovoMix 50 FlexPen 100 units/ml suspension for injection in pre-filled pen

A insulin degludec und insulin aspart product containing insulin aspart, registered in Ireland by Novo Nordisk A/S. The same ATC class is registered in 9 of our 19 countries.

ATC A10AD06

Checked against HPRA (Ireland) on

Informational only — not a medical device.

SOURCE REGISTER · IEHPRA (Ireland)normalisedNovoMix 50 FlexPen 100 units/ml suspe…ATCA10AD06REGISTER NO.IE-PA-EU/1/00/142/14-…PACKS LISTED1CHECKEDSeptember 28, 2026

Where it is registered

Insulin degludec und insulin aspart is registered in 9 of 19 countries.

Countries holding a registration under ATC A10AD06 (insulin degludec und insulin aspart), each read from that country’s own register.

  • This record: Ireland, from HPRA (Ireland)
  • 6 of them publish a price we can compare per daily dose

Insulin degludec und insulin aspart · ATC A10AD06

9 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

HPRA (Ireland)
Active substance
Insulin aspart
Manufacturer
Novo Nordisk A/S
Country
Ireland (IE)
ATC code
A10AD06
ATC class
Insulin degludec und Insulin aspart
Defined daily dose
40 E, P
Reimbursed
Not published by this register
Source register
HPRA (Ireland)
Last checked
September 28, 2026

Packs & prices · 1

  • ie_pa_number
    EU/1/00/142/14-16

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Insulin degludec und insulin aspart in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All insulin degludec und insulin aspart products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Dazparda, Fiasp
  • Liechtenstein · Dazparda, Insulin Aspart Sanofi
  • Norway · Dazparda, Fiasp

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/6a0453f8-2812-46e2-9887-ff1c542282eb
GET /v1/drugs/6a0453f8-2812-46e2-9887-ff1c542282eb?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Suspension for injection",
  "routes": [
    "Subcutaneous use"
  ],
  "source": "hpra",
  "atc_all": [
    "A10AD",
    "A10AD06"
  ],
  "strength": null,
  "pa_number": "EU/1/00/142/14-16",
  "substances": [
    "Insulin aspart"
  ],
  "legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
  "market_info": "Unknown",
  "authorised_at": null,
  "dispensing_status": "Product subject to prescription which may be renewed (B)",
  "registration_status": "AU",
  "supply_legal_status": "Supply through pharmacies only",
  "interchangeable_code": null
}

See everything about insulin degludec und insulin aspart.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.